HRGN Harvard Apparatus Regenerative Technology, Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1563665 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY35.1%
TTM net income YoY1.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin7.5%
Operating margin-643.0%
Net margin-642.0%
FCF margin—
EBITDA margin-642.6%
Returns
ROE-621.0%
ROA-225.6%
ROIC (approx.)—
Asset turnover0.35x
Leverage & solvency
Liabilities / assets83.5%
Debt / equity0.00x
Current ratio0.87x
Interest coverage-269.00x
Cash quality & payout
Operating cash flow / net income0.43x
Accruals ratio-127.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $704,000 | $430,000 | $103,000 | — | $0 |
| Cost of revenue | $646,000 | $270,000 | $24,000 | — | — |
| Gross profit | $58,000 | $160,000 | $79,000 | — | — |
| R&D expense | $2.65M | $2.31M | $3.06M | $1.74M | $1.59M |
| SG&A expense | $4.25M | $5.02M | $5.71M | $4.41M | $7.04M |
| Operating income | -$6.92M | -$7.73M | -$8.99M | -$6.15M | -$8.64M |
| Interest expense | $8,000 | $38,000 | $14,000 | $9,000 | — |
| Pretax income | -$6.87M | -$7.73M | — | — | — |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$6.87M | -$7.73M | -$8.95M | -$6.07M | -$7.98M |
| EBITDA | -$6.91M | -$7.71M | -$8.96M | -$6.10M | -$8.53M |
| EPS (basic) | -0.42 | -0.52 | -0.67 | -0.55 | -0.79 |
| EPS (diluted) | — | — | -0.67 | -0.55 | -0.79 |
| Weighted avg. shares (diluted) | — | — | 13.46M | 11.35M | 10.06M |
| Balance sheet | |||||
| Cash & equivalents | $1.35M | $2.49M | $432,000 | $1.24M | $1.29M |
| Short-term investments | — | — | $1.20M | — | — |
| Receivables | $16,000 | $231,000 | $4,000 | — | — |
| Inventory | $16,000 | $80,000 | $50,000 | — | — |
| Current assets | $1.83M | $3.23M | $783,000 | $1.59M | $1.59M |
| PP&E, net | $6,000 | $11,000 | $25,000 | $49,000 | $110,000 |
| Total assets | $2.68M | $4.44M | $2.61M | $2.40M | $1.87M |
| Current liabilities | $1.53M | $1.02M | $968,000 | $1.36M | $4.84M |
| Total liabilities | $1.62M | $1.22M | $968,000 | $1.41M | $4.89M |
| Shareholders' equity | $1.06M | $3.22M | $1.65M | -$3.19M | -$3.03M |
| Shares outstanding | 17.58M | 15.92M | 13.95M | 12.17M | 10.76M |
| Cash flow statement | |||||
| Operating cash flow | -$3.83M | -$4.85M | -$6.94M | -$5.11M | -$2.63M |
| Capital expenditure | — | $0 | $11,000 | $5,000 | $0 |
| Free cash flow | — | -$4.85M | -$6.95M | -$5.11M | -$2.63M |
| Investing cash flow | — | $0 | -$11,000 | -$5,000 | $0 |
| Financing cash flow | $2.70M | $6.91M | $6.14M | $5.06M | $2.84M |
| Depreciation & amortization | $5,000 | $14,000 | $35,000 | $52,000 | $107,000 |
| Stock-based compensation | $2.01M | $2.40M | $3.46M | $1.03M | $980,000 |
| Share buybacks | — | — | — | — | $0 |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.